Observational studyJournal of cosmetic dermatology2026
Post-Botulinum Headache in Cosmetic Practice: A Prospective Study.
Observational study in Journal of cosmetic dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Comment on "Post-Botulinum Headache in Cosmetic Practice: A Prospective Study".Journal of cosmetic dermatology · 2026Article
- Monitoring complications of botulinum toxin in community practice: A pharmacological study.Bioinformation · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBotulinum toxin is widely used for aesthetic and functional indications and is generally considered safe; however, post-procedural headache remains a recognized but underexplored adverse effect, particularly in cosmetic practice.
objectiveTo evaluate the incidence, characteristics, and potential risk factors of headache following botulinum toxin injections administered to different anatomical regions.
methodsThis prospective observational study included 102 adult patients undergoing abobotulinumtoxinA injections to the upper facial regions, masseter muscles, and/or axillary area. Headache occurrence was assessed on day 3 by telephone, at days 10-12 during follow-up visits, and through patient-initiated contact within the first month. Demographic variables, prior botulinum toxin exposure, injection-related pain, toxin dose, and headache characteristics were recorded.
resultsPost-botulinum headache occurred in 13 patients (12.7%) and was generally mild-to-moderate, short-lived, and self-limited. Headache was significantly more frequent in first-time recipients compared with previously treated patients (45.5% vs. 8.8%, p = 0.005). All patients who developed headache had received injections involving the upper facial regions, whereas no headache was observed after exclusive masseter or axillary treatments. No associations were found with toxin dose, procedural pain, or systemic comorbidities.
conclusionPost-botulinum headache is an infrequent, benign, and transient event, predominantly affecting first-time patients undergoing upper facial injections. These findings may aid clinicians in patient counseling and expectation management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.